Background: The role of Axl and LC3 as predictors of tumor recurrence and overall
| INTRODUCTION
Hepatocellular carcinoma (HCC) is the third common cause of cancer-related death in the world. 1, 2 In Taiwan, viral-and alcohol-related cirrhosis frequently result in HCC. 3 Moreover, HCC is hard to diagnose at the very early and early stages, resulting in higher mortality rates worldwide. 1,2 Although the 5-year survival rate of individuals diagnosed in the early stage exceeded 50% after curative resection, these patients still had a high recurrence rate of approximately 60% after curative resection. [4] [5] [6] [7] [8] The highly sensitive marker alpha-fetoprotein (AFP) predicts clinical outcome in HCC patients after hepatectomy, but the result is still unsatisfactory. 9 Hence, the identification of biomarkers for HCC recurrence and overall survival (OS) could help improve the clinical prognosis of HCC patients undergoing hepatectomy. Axl, a member of the Tyro3, Mer, and Axl family of tyrosine kinase receptors, regulates some aspects of cancer biology. 10 The Axl-mediated signaling pathway is frequently affected in the development and progression of various cancers, including brain cancer, breast cancer, and pancreatic cancer. [11] [12] [13] Recently, Reichl et al reported that high serum levels of soluble Axl are correlated with vascular involvement and lymph node metastasis, and the serum level of soluble Axl is a potential biomarker for the early diagnosis of HCC and the early prediction of HCC recurrence. 14 Moreover, Wu et al demonstrated that Axl overexpression/hyperactivation plays a major role in epithelial-to-mesenchymal transition, cancer chemotherapy resistance, and increased metastasis, all of which implicate Axl as an important target. 15 Several studies showed that Axl may be a negative predictor for HCC patients, and high Axl expression was positively associated with differentiation, lymph node metastasis, higher recurrence rates, and lower survival rates in HCC patients. 16, 17 Furthermore, Axl expression was associated with increased tumor invasion and predicted a worse prognosis for HCC patients undergoing resection. 18 Our previous studies showed that high LC3 expression in the liver and tumor microenvironments is strongly correlated with higher OS and lower HCC recurrence. 7, 8 However, whether Axl expression is associated with clinical prognosis in HCC patients remains largely unknown. In addition, the role of Axl and the autophagy-related marker LC3 in OS and HCC recurrence is not clear. Hence, we investigate the impact of Axl and LC3 expression on tumor recurrence and OS in a large cohort of HCC patients who underwent curative resection.
| MATERIALS AND METHODS

| Patients and follow-up
We retrospectively collected the data from 535 HCC patients who underwent resection from 2010 to 2014 at Changhua Christian Hospital, Changhua, or E-Da Hospital, I-Shou University, Kaohsiung, Taiwan. All participants were regularly followed-up every three to six months after surgery. The last recorded follow-up was on 31 December 2016. OS was the duration from the date of hepatectomy to the date of death or the last visit. Survival data were censored on the end-data of follow-up. Time to recurrence was the duration from the date of hepatectomy to the date of recurrence. HCC recurrence was based on histology or at least two typical HCC imaging methods according to the HCC guidelines of the American Association for the Study of Liver Disease. 19 The clinicopathological features of the patients, such as demographic data and tumor characteristics, were recorded. Antiviral treatment was defined as patients with hepatitis B virus (HBV), hepatitis C virus (HCV), or dual HBV/HCV infection who received therapy with oral nucleosides, pegylated interferon-based therapy or direct-acting agents according to the guidelines of the Taiwan Association for the Study of the Liver. This research was approved by the Institutional Review Boards of Changhua Christian Hospital (091107) and E-DA Hospital (EMRP38104N). The research was conducted according to the guidelines of the International Conference on Harmonization for Good Clinical Practice. All participants were adults and provided written informed consent for study participation.
| Immunohistochemical staining and scoring
Tissue microarrays were constructed as previously described 7 and subjected to immunohistochemistry (IHC).
The tissues were stained with an anti-Axl antibody (Santa Cruz, CA) and an anti-LC3 antibody (Novus Biologicals, CO). Axl and LC3 expression was quantitated using the semiquantitative immunoreactive scoring system (IRS) as described previously, 20 and the expression was defined as either negative (IRS < 2) or positive (IRS ≥ 2) according to the percentage and intensity scores. All tissues were independently assessed by two investigators who were blinded to the clinical data.
| Data analysis and statistics
Numerical data are presented as the mean (range). Categorical data are described using numbers (percentages 3 | RESULTS
| Baseline demographic data
The demographic and clinicopathological features of the 535 patients are presented in Table 1 
| Predictive factors associated with tumor recurrence in HCC patients who underwent hepatectomy
HCC recurrence occurred in 245 patients, and the HCC recurrence rate at 1, 3, 5, and 7 years after hepatectomy was 9.7%, 33.9%, 53.3% and 66.3%, respectively. In the univariate analysis, macrovascular invasion, liver cirrhosis, high Axl expression in tumors and low LC3 expression in tumors were significantly correlated with increased HCC recurrence ( Table 2 ). The multivariate Cox regression analysis revealed that high Axl expression in tumors was significantly correlated with increased HCC recurrence (hazard ratio [HR]: 3.85, 95% confidence interval [CI]: 2.95-5.02, P < 0.001), but high LC3 expression in tumors was significantly correlated with decreased HCC recurrence (HR: 0.38, 95% CI: 0.26-0.55, P < 0.001), as shown in Table 2 .
Patients with high Axl expression in tumors had a significantly higher HCC recurrence rate than those with low Axl expression in tumors by Kaplan-Meier analysis. In patients with high and low Axl expression in tumors, the 1-, 3-, 5-and 7-year HCC recurrence rates were 19.3%, 58.6%, 77.9% and 85.9% and 3.0%, 17.2%, 37.1% and 53.7%, respectively ( Figure 1A) .
T A B L E 1 Basic demographic data of all patients and correlations between tumor Axl expression and clinicopathologic characteristics
Characteristics
All patients (n = 535) Axl-low (n = 305) Axl-high (n = 230) P-value In addition, patients with low LC3 expression in tumors had a significantly higher HCC recurrence rate than those with high LC3 expression in tumors. In patients with low and high LC3 expression in tumors, the 1-, 3-, 5-and 7-year HCC recurrence rates were 15.6%, 39.2%, 73.3% and 94.9% and 8.4%, 26.7%, 37.9% and 69.5%, respectively ( Figure 1B ).
| Predictive factors associated with OS in HCC patients who underwent hepatectomy
The median follow-up time was 42 months, and 219 patients died. The OS rates at 1, 3, 5 and 7 years after resection were 91.0%, 72.3%, 58.8%, and 27.7%, respectively. In the univariate analysis, the following factors were significantly correlated with OS: sex, HBV-related HCC, cirrhosis, antiviral treatment, the presence of macrovascular and microvascular invasion, primary tumor size, BCLC stage, HCC recurrence, Axl expression in tumors and LC3 expression in tumors.
The multivariate Cox regression analysis showed that patients with HCC recurrence had the highest mortality (HR: 2.87, 95% CI: 2.01-4.01, P < 0.001), followed by those with microvascular invasion (HR: 1.85, 95% CI: 1.08-3.19, P = 0.026), HBV-related HCC (HR: 1.77, 95% CI: 1.21-2.56, P = 0.003), and high Axl expression in tumors (HR: 1.66, 95% CI: 1.41-1.97, P < 0.0001); these data are summarized in Table 3 . Mortality was also significantly decreased in patients receiving antiviral treatment (HR: 0.54, CI: 0.38-0.76, P < 0.001) and in those with high LC3 expression in tumors (HR: 0.41, 95% CI: 0.28-0.58, P < 0.001), as shown in Table 3 .
Patients with high Axl expression in tumors had significantly lower OS than those with low Axl expression in tumors. In patients with high and low Axl expression in tumors, the 1-, 3-, 5-and 7-year OS rates were 83.0%, 51.3%, 28.8% and 15.6% and 97.0%, 87.8%, 79.3% and 38.4%, respectively (Figure 2A) . In addition, patients with low LC3 expression in tumors had significantly lower OS than those with high LC3 expression in tumors. In patients with low and high LC3 expression in tumors, the 1-, 3-, 5-and 7-year OS rates were 84.4%, 60.8%, 26.7% and 5.1% and 91.6%, 73.3%, 62.1% and 30.5%, respectively ( Figure 2B ).
F I G U R E 1
Cumulative incidence of tumor recurrence according to Axl and LC3 expression in tumors. The cumulative incidence of HCC recurrence is significantly lower in patients with low Axl expression than in those with high Axl expression (A). The cumulative incidence of HCC recurrence is significantly lower in patients with high LC3 expression than in those with low LC3 expression (B). −, low; +, high; HCC, hepatocellular carcinoma. 
Characteristics
| Tumor recurrence and OS according to combined Axl and LC3 expression
Next, the combination of Axl and LC3 expression in tumors was analyzed. For HCC recurrence, compared to patients (n = 289) with low Axl and high LC3 expression in tumors, patients (n = 29) with high Axl and low LC3 expression had the highest risk of HCC recurrence (HR: 6.53, 95% CI: 4.11-10.4, P < 0.001), followed by those (n = 201) with high Axl and high LC3 expression Figure 3A) . Moreover, compared with patients with low Axl and high LC3 expression in tumors, patients with high Axl and low LC3 expression had the highest risk of mortality (HR: 6.66, 95% CI: 4.07-10.9, P < 0.001), followed by those with high Axl and high LC3 expression (HR: 5.48, 95% CI: 3.98-7.54, P < 0.001) and those with low Axl and low LC3 expression (HR: 4.45, 95% CI: 2.39-8.29, P < 0.001).
The results showed that patients with low Axl and high LC3 expression in HCC tissues had 1-, 3-, 5-and 7-year OS rates of 96.9%, 88.2%, 82.2% and 41.6%, respectively. Data are shown as the mean ± standard deviation or number (%). Abbreviations: AFP, alpha-fetoprotein; BCLC, Barcelona clinic liver cancer; CI, confidence interval; HBV, hepatitis B virus; HCV, hepatitis C virus; HR, hazard ratio.
T A B L E 3 (Continued)
F I G U R E 2 Cumulative incidence of overall survival according to Axl and LC3 expression in tumors. The cumulative incidence of overall survival is significantly higher in patients with low Axl expression than in those with high Axl expression (A). The cumulative incidence of overall survival is significantly higher in patients with high LC3 expression than in those with low LC3 expression (B). −, low; +, high; HCC, hepatocellular carcinoma.
Compared with this group, the low Axl/low LC3 group (100%, 80.4%, 34.7% and 0%, respectively), high Axl/ high LC3 group (84.1%, 51.7%, 30.0% and 16.8%, respectively) and high Axl/low LC3 group (75.9%, 49.2%, 16.8% and 8.4%, respectively) had significantly lower OS rates ( Figure 3B ).
| DISCUSSION
In this study, 535 HCC patients who underwent curative resection were analyzed to identify predictive factors for HCC recurrence and OS. High Axl expression in tumors was significantly associated with advanced clinicopathological features, high HCC recurrence rates, and low OS rates. In addition, low LC3 expression in tumors was also significantly correlated with high HCC recurrence and low OS rates. Furthermore, the combined expression of Axl and LC3 in tumors was analyzed. Patients with high Axl and low LC3 expression in tumors had the highest HCC recurrence (HR: 6.53; P < 0.001) and mortality rates (HR: 6.66; P < 0.001). These findings suggest that Axl and LC3 expression levels in tumors may serve as predictors of HCC recurrence and OS after hepatectomy for HCC. Several studies showed that high Axl expression in HCC patients was positively associated with more aggressive tumor invasiveness, a high risk of tumor recurrence, lymph node metastasis, and lower survival. 16 expression in tumors in the prognosis of HCC recurrence and OS. The study is the first to demonstrate that Axl and LC3 expression in tumors is significantly associated with HCC recurrence and OS. The combination of high Axl and low LC3 expression in tumors significantly increases the risk of HCC recurrence and mortality in HCC patients after hepatectomy.
Our study showed that high Axl expression in tumors increased HCC recurrence (HR: 3.85) and mortality (HR: 1.66) compared with low Axl expression and that high LC3 expression in tumors decreased HCC recurrence (HR: 0.38) and mortality (HR: 0.41) compared with low LC3 expression. Furthermore, high Axl and low LC3 expression in tumors increased HCC recurrence (HR: 6.53) and mortality (HR: 6.66) compared with low Axl and high LC3 expression. We aimed to find better markers to precisely predict HCC recurrence and mortality. Axl expression in tumors was a better predictor than LC3 expression of HCC recurrence. The combination of Axl and LC3 expression in tumors by IHC staining significantly predicted HCC recurrence and mortality compared with the expression of either marker alone. The combination of two markers was a better predictor of HCC recurrence and mortality than a single marker. In clinical practice, tumor tissues may be subjected to IHC staining for Axl and LC3 after hepatectomy. Patients with high Axl and low LC3 expression in tumors will be identified as having a higher risk of HCC recurrence and mortality than those with low Axl and high LC3 expression in tumors. Close postoperative follow-up is suggested for this patient population to increase the detection rate of early-stage HCC, and further aggressive management may prolong the survival of these high-risk patients.
This study had some limitations. First, this study was retrospective, which could have introduced unintended bias. Second, cirrhotic patients composed only one-third of our cohort, while other studies have included a majority of cirrhosis patients (80%). This difference in prevalence of cirrhosis may have affected the generalizability of the outcomes. Finally, the underlying mechanism of Axl and LC3 expression related to carcinogenesis and clinical prognosis needs to be further investigated in vivo and in vitro.
In summary, high Axl expression in tumors is significantly associated with advanced clinicopathological features, high HCC recurrence rate, and low OS rate. In addition, low LC3 expression in tumors is also significantly associated with high HCC recurrence and low OS rates. Furthermore, patients with a combination of high Axl expression and low LC3 expression in tumors had higher HCC recurrence and lower OS rates. This study is the first to demonstrate that the combined Axl and LC3 expression pattern in the tumor microenvironment is critical for predicting HCC recurrence and OS. Analysis of Axl and LC3 expression in tumors, in conjunction with clinicopathological features, could identify predictors of HCC recurrence and OS after curative hepatectomy. Our results indicated that the combination of high Axl and low LC3 expression significantly correlated with HCC recurrence and OS and that Axl and LC3 may serve as potential biomarkers for predicting HCC recurrence and OS.
